JP2023511472A5 - - Google Patents

Info

Publication number
JP2023511472A5
JP2023511472A5 JP2022525186A JP2022525186A JP2023511472A5 JP 2023511472 A5 JP2023511472 A5 JP 2023511472A5 JP 2022525186 A JP2022525186 A JP 2022525186A JP 2022525186 A JP2022525186 A JP 2022525186A JP 2023511472 A5 JP2023511472 A5 JP 2023511472A5
Authority
JP
Japan
Prior art keywords
group
alkyl
linker
hydrogen
existence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/080265 external-priority patent/WO2021083949A1/en
Publication of JP2023511472A publication Critical patent/JP2023511472A/ja
Publication of JP2023511472A5 publication Critical patent/JP2023511472A5/ja
Pending legal-status Critical Current

Links

JP2022525186A 2019-10-29 2020-10-28 がんの治療のための二官能性化合物 Pending JP2023511472A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962927340P 2019-10-29 2019-10-29
US62/927,340 2019-10-29
EP19209344 2019-11-15
EP19209344.1 2019-11-15
PCT/EP2020/080265 WO2021083949A1 (en) 2019-10-29 2020-10-28 Bifunctional compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023511472A JP2023511472A (ja) 2023-03-20
JP2023511472A5 true JP2023511472A5 (cg-RX-API-DMAC7.html) 2023-11-01

Family

ID=73020226

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525186A Pending JP2023511472A (ja) 2019-10-29 2020-10-28 がんの治療のための二官能性化合物

Country Status (5)

Country Link
US (1) US20230024096A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051674A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023511472A (cg-RX-API-DMAC7.html)
CN (1) CN114728936A (cg-RX-API-DMAC7.html)
WO (1) WO2021083949A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP7871189B2 (ja) * 2019-12-17 2026-06-08 オリオニス バイオサイエンシズ,インコーポレイテッド タンパク質の動員および/または分解を調節する化合物
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CR20230518A (es) * 2021-05-10 2024-02-13 Foghorn Therapeutics Inc Compuestos y usos de estos
WO2022243333A1 (en) 2021-05-17 2022-11-24 Universität Zürich N6-adenosine-methyltransferase inhibitors in cancer treatment
WO2022272133A2 (en) * 2021-06-25 2022-12-29 Stablix, Inc. Protein stabilizing compounds containing usp7 ligands
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
JP2024533990A (ja) * 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
WO2023039573A1 (en) * 2021-09-10 2023-03-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
AU2023292503A1 (en) * 2022-06-15 2024-10-31 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
CN117384161A (zh) * 2022-07-04 2024-01-12 华东理工大学 靶向降解cdk蛋白的化合物及其应用
CN119923394A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116120311B (zh) * 2022-11-28 2025-10-24 中国药科大学 一种靶向降解atr蛋白的双功能化合物及其制法与用途
CN116284202B (zh) * 2023-03-28 2024-07-02 华侨大学 白桦脂酸的PROTACs化合物及其制备方法和应用
CN121013852A (zh) * 2023-04-14 2025-11-25 南京再明医药有限公司 Brm选择性降解剂及其应用
TW202502750A (zh) 2023-06-08 2025-01-16 美商新銳思生物製藥股份有限公司 Smarca2之雙官能選擇性降解劑及其治療用途
IL325247A (en) * 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
WO2025006902A2 (en) * 2023-06-29 2025-01-02 Dana-Farber Cancer Institute, Inc. Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1)
WO2025061035A1 (zh) * 2023-09-19 2025-03-27 南京再明医药有限公司 Brm选择性降解剂化合物及其应用
WO2025094065A1 (en) 2023-11-01 2025-05-08 Aurigene Oncology Limited Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
CN122070278A (zh) * 2024-09-19 2026-05-19 标新生物医药科技(上海)有限公司 含有芳基取代杂芳基的双功能蛋白降解剂及其应用
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof
WO2026128580A2 (en) 2024-12-11 2026-06-18 Nurix Therapeutics, Inc. Bifunctional selective degraders of smarca2 and therapeutic uses thereof
CN119798218A (zh) * 2024-12-31 2025-04-11 南京优氟医药科技有限公司 一种e3酶配体-连接链复合物及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533A (en) 1837-12-26 Truss for hermta
US4943A (en) 1847-01-26 Harness-buckle
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
SG10201900631TA (en) * 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
EP3189049B1 (en) * 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20230087825A1 (en) * 2019-06-10 2023-03-23 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US12624044B2 (en) * 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof

Similar Documents

Publication Publication Date Title
JP2023511471A5 (cg-RX-API-DMAC7.html)
Balaji et al. Synthesis and structure of arene Ru (II) N∧ O-chelating complexes: in vitro cytotoxicity and cancer cell death mechanism
Jopp et al. Anticancer activity of a series of copper (II) complexes with tripodal ligands
EP0471709B1 (en) Ruthenium(iii) complexes as antineoplastic agents
Koch et al. Synthesis, characterization, and biological properties of steroidal ruthenium (II) and iridium (III) complexes based on the androst-16-en-3-ol framework
Yousef et al. Benzohydrazide derivative metal complex's antimicrobial and inhibitory effects on liver cancer cell lines and quinone oxidoreductase 2: Experimental, molecular docking, and DFT investigations
Anusionwu et al. Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines
Crabtree Some chelating C-donor ligands in hydrogen transfer and related catalysis
Pal et al. Exploring the effect of Ru (ii) arene complexes on cytotoxicity upon co-ligand variation and loading on amine-functionalized silica nanoparticles
JP5769831B2 (ja) イソホスホルアミドマスタードおよびその類似体の合成および製剤
Barbanente et al. New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases
JP2010523571A5 (cg-RX-API-DMAC7.html)
DeBord et al. Synthesis, characterization, and in vitro SAR evaluation of N, N′-bis (arylmethyl)-C2-alkyl substituted imidazolium salts
NZ535366A (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use
AU716220B2 (en) New salts of anionic complexes of RU(III), as antimetastatic and antineoplastic agents
WO2011078122A1 (ja) 抗がん剤
Mu et al. Ruthenium anticancer compounds with biologically‐derived ligands
RU2024136909A (ru) Соединения для направленной деградации smarca2
CN101163710A (zh) 膦过渡金属配位化合物、其制造方法和含有其的抗癌剂
TW393488B (en) Process for making 1-hydrox-ybisphosphonates
WO2019110006A1 (zh) 抗疼痛化合物及其制备方法
JP2021523936A (ja) 金(iii) 錯体、金(iii) 錯体のコンジュゲート、金(iii) 錯体を含む医薬組成物、金(iii) 錯体を生成する方法とその使用。
Artyushin et al. Water as a promoting media for 1, 3-dipolar cycloaddition of phosphorylated azides to internal alkynes.
JP5746693B2 (ja) セレノキノン由来の活性有機金属錯体、該錯体の製造方法、および、該錯体の用途
WO2013146437A1 (ja) 3-デセン酸誘導体およびその用途